Engineered T cells for adoptive immunotherapy
Patent Information
- Application Number
- JP2023530946
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-21
- Filing Date
- 2021-12-01
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-12-01
AI Technical Summary
Cancer-derived immunosuppressive factors impair sentinel lymph node immunity, allowing tumors to invade and metastasize, necessitating a method to enhance T cell antitumor efficacy.
Downregulate SIGLEC15 expression in T cells extracted from tumor-draining lymph nodes using siRNA, shRNA, or CRISPR-mediated gene editing, and amplify these cells under interleukin-2 conditions to support T cell expansion.
T cells with reduced SIGLEC15 expression exhibit increased release of antitumor cytokines IL-2, TNF-α, and IFN-γ, enhancing their therapeutic potential against cancers such as colorectal, malignant melanoma, cervical, and non-small cell lung cancer.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to the field of therapeutic treatments. In particular, the present invention relates to cancer treatments based on the administration of autologous cells to patients in need thereof, cells useful in such treatments, and methods for preparing such cells. [Background technology]
[0002] Adoptive immunotherapy using autologous, in vitro expanded lymphocytes isolated from tumor-draining sentinel lymph nodes is known in the art (1), and adoptive immunotherapy involving the collection and expansion of autologous tumor-reactive lymphocytes and their reinfusion into patients has been explored in malignant melanoma (2).
[0003] WO2018 / 234516 teaches a method for expanding anti-tumor T cells with phagocytosable particles bearing one or more tightly associated tumor neo-antigen constructs.
[0004] Adoptive T cell transfer therapy, in which autologous or allogeneic T cells are infused into patients with cancer, has recently shown considerable promise ( 3 ).
[0005] Siglecs are vertebrate cell surface receptors that recognize sialylated glycans. SIGLEC15 is a type I transmembrane protein consisting of (i) two immunoglobulin (Ig)-like domains, (ii) a transmembrane domain containing lysine residues, and (iii) a short cytoplasmic tail. SIGLEC15 is expressed on macrophages and / or dendritic cells in the human pancreas and lymph nodes (4). SIGLEC15 messenger RNA expression is minimal in most normal human tissues and various immune cell subsets, but it can be found in macrophages, most abundantly in M2 macrophages (4). SIGLEC15 not only regulates osteoclast differentiation but also suppresses T cell responses (5).
[0006] US2019 / 202912 suggests using antibodies that bind to SIGLEC15 in cancer treatment. Summary of the Invention [Problem to be solved by the invention]
[0007] The inventors surprisingly found that downregulation of SIGLEC15 in T cells derived from sentinel lymph nodes can attenuate the immune compromise brought about by cancer-derived immunosuppressants and thus attenuate the ability of tumors to invade and metastasize. [Means for solving the problem]
[0008] Thus, in a first aspect, the present invention provides a method for obtaining a population of T cells having reduced expression of SIGLEC15, comprising: S1. Identifying lymph nodes in a subject that drain lymph from a cancerous tumor; S2. Extracting cells from the identified lymph nodes; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells in which SIGLEC15 expression is reduced under conditions that support T cell expansion; The present invention relates to a method comprising:
[0009] In a second aspect, the present invention provides a method for obtaining a population of T cells having reduced expression of SIGLEC15, comprising: S1'. Providing T cell-containing lymph node tissue removed from a subject, said lymph node tissue being obtained from a lymph node identified in said subject as draining lymph from a cancerous tumor; S2. Extracting cells from the identified lymph nodes; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells in which SIGLEC15 expression is reduced under conditions that support T cell expansion; The present invention relates to a method comprising:
[0010] In some embodiments, the expression of SIGLEC15 is reduced by downregulating the expression of the gene encoding SIGLEC15 by siRNA transfection, shRNA transfection, or CRISPR-mediated gene editing.
[0011] In some embodiments, the expression of SIGLEC15 is reduced by downregulating the expression of the gene encoding SIGLEC15 by siRNA transfection using an siRNA molecule having the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
[0012] In some embodiments, the conditions that support T cell expansion include maintaining the cells in the presence of interleukin-2.
[0013] In a further aspect, the present invention relates to a population of T cells with reduced expression of SIGLEC15, obtainable by a method according to the present invention.
[0014] In a further aspect, the present invention relates to a population of T cells according to the invention for use in medicine.
[0015] In a further aspect, the present invention relates to a population of T cells according to the invention for use in a method for the treatment of cancer.
[0016] In some embodiments, the cancer is a solid tumor.
[0017] In some embodiments, the cancer is a cancerous tumor in the subject from which the T cells are derived, or a metastasis thereof.
[0018] In some embodiments, the cancer is selected from the group of colorectal cancer, malignant melanoma, cervical cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC).
[0019] In a further aspect, the present invention provides a method for treating a cancerous tumor in a subject, comprising: S1. Identifying lymph nodes in the subject that drain lymph from a cancerous tumor; S2. Extracting cells from the identified lymph nodes; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells having reduced expression of SIGLEC15 under conditions that support T cell expansion; S5. Administering expanded T cells with reduced SIGLEC15 expression; The present invention relates to a method comprising:
[0020] In some embodiments, the expression of SIGLEC15 is reduced by downregulating the expression of the gene encoding SIGLEC15 by siRNA transfection, shRNA transfection, or CRISPR-mediated gene editing.
[0021] In some embodiments, the expression of SIGLEC15 is reduced by downregulating the expression of the gene encoding SIGLEC15 by siRNA transfection using an siRNA molecule having the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
[0022] In some embodiments, the cancer is a solid tumor.
[0023] In some embodiments, the cancer is a cancerous tumor in the subject from which the T cells are derived, or a metastasis thereof.
[0024] In some embodiments, the cancer is selected from the group of colorectal cancer, malignant melanoma, cervical cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC).
[0025] In a further aspect, the present invention relates to the use of a population of T cells according to the invention in the preparation of a pharmaceutical composition for use in a method of treatment according to the invention.
[0026] In a further aspect, the present invention relates to a pharmaceutical composition comprising a population of T cells according to the present invention and optionally a pharmaceutically acceptable excipient and or carrier. [Brief explanation of the drawings]
[0027] [Figure 1] FIG. 1 shows a flow chart illustrating a method for obtaining a population of T cells according to the present invention. [Figure 2] FIG. 1 shows a flow chart illustrating a method of treatment according to the present invention. [Figure 3A] Figure 1 shows the relative expression of SIGLEC15 in sentinel and non-sentinel lymph nodes, respectively. [Figure 3B] Figure 1 shows the relative expression of SIGLEC15 in sentinel lymph nodes before and after siRNA knockdown. [Figure 4A] 1 shows protein expression of SIGLEC15 in various cell types, showing a comparison between sentinel nodes (SN) and non-sentinel nodes (NSN) across cell types. [Figure 4B] 1 shows protein expression of SIGLEC15 in various cell types. Comparison across cell types for sentinel nodes (SN). [Figure 5] FIG. 1 shows T cell functional cytokine release after SIGLEC15 knockdown. DETAILED DESCRIPTION OF THE INVENTION
[0028] Lymph nodes draining primary tumors are critical for mounting effective antitumor T cell immune responses. However, cancer-derived immunosuppressive factors impair sentinel lymph node (SN) immunity, allowing tumors to invade and metastasize.
[0029] The present inventors have investigated the various mechanisms underlying this immune escape in order to devise therapeutic interventions to halt tumor spread at an early clinical stage. Thus, the present invention utilizes an understanding of the microenvironmental regulation of transcription levels in the lymph nodes of cancer patients, for example, colorectal cancer patients.
[0030] Several cytokines limit tumor cell growth through direct antiproliferative or proapoptotic activity or indirectly by stimulating the cytotoxic activity of immune cells against tumor cells. Interleukin-2 (IL-2) is considered an important cytokine in promoting the expansion of natural killer (NK) cells and T lymphocytes. NK cells and T cells are the major lymphocyte subsets responsible for tumor killing. Tumor necrosis factor α (TNF-α) is primarily considered a mediator of antitumor immune responses. Interferon-γ (IFN-γ) is a pleiotropic molecule with associated antiproliferative, proapoptotic, and antitumor mechanisms. IFN-γ release is an important efficacy indicator, for example, in the quality assessment of the CAR-T cell product tisagenlecleucel (6).
[0031] T cells isolated from tumor-draining lymph nodes and treated to reduce SIGLEC15 expression have been found to have improved antitumor efficacy as assessed by the effector cytokine release profile described above. As disclosed in the experimental section below, T cells with reduced SIGLEC15 expression exhibit increased release of the cytokines IL-2, TNF-α, and IFN-γ.
[0032] The present invention relates, in part, to the use of autologous T cells that have been treated to reduce the expression of SIGLEC15 in cancer therapy, and corresponding methods of treatment. The invention also relates to methods for preparing and obtaining such T cells, T cells obtained or obtainable by such methods, and pharmaceutical compositions comprising such T cells.
[0033] Thus, in a first aspect, the present invention provides a method for obtaining a population of T cells having reduced expression of SIGLEC15, comprising: S1. Identifying lymph nodes in a subject that drain lymph from a cancerous tumor; S2. Extracting cells from the identified lymph nodes; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells in which SIGLEC15 expression is reduced under conditions that support T cell expansion; The present invention relates to a method comprising:
[0034] In a further aspect, the present invention provides a method that does not involve any surgical steps performed on the human or animal body, for obtaining a population of T cells having reduced expression of SIGLEC15, said method comprising: S1'. Providing T cell-containing lymph node tissue removed from a subject, said lymph node tissue being obtained from a lymph node identified in said subject as draining lymph from a cancerous tumor; S2. Extracting cells from the identified lymph nodes; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells in which SIGLEC15 expression is reduced under conditions that support T cell expansion; The present invention relates to a method, including:
[0035] The above method is shown diagrammatically in FIG.
[0036] Identification of lymph nodes as draining lymphatic fluid from a cancerous tumor can be performed as known in the art, for example, as described by Dahl and colleagues (7). Briefly, a detectable and physiologically acceptable dye is injected into or around the tumor. The lymphatic fluid carries the dye from the injection site to the draining lymph nodes, which are then stained by the dye and identified as draining lymph nodes. Exemplary dyes are patent blue, Evans blue, and Alexa Fluor® 488 dye.
[0037] Extraction of cells from lymph nodes identified as draining lymph nodes can be performed in a variety of ways. The entire lymph node can be removed from the patient by resection. Alternatively, it is possible to obtain only a piece of lymph node tissue, for example, through a biopsy. The extracted cells of lymph node tissue can be made into a single-cell suspension, as is known in the art (8).
[0038] The expression of SIGLEC15 in the extracted cells is then reduced.
[0039] In some embodiments, SIGLEC15 expression is reduced by downregulating the expression of the gene encoding SIGLEC15 through siRNA transfection. Briefly, single lymph node cells can be transfected with siRNA. 1 μmol / L of siRNA can be transfected into a 96-well tissue culture plate containing Accell siRNA delivery vehicle (GE Dharmacon) for 72 hours according to the manufacturer's instructions. RT-PCR is typically used to evaluate SIGLEC15 mRNA expression in siRNA-transfected and non-transfected groups. Other protocols are well known in the art (9) and will not be described in detail here. Additionally, protocols and reagents for downregulating the expression of specific genes with siRNA are commercially available without preconception from several companies, including ThermoFisher Scientific, Sigma-Aldrich, Qiagen, and GE Dharmacon.
[0040] In some embodiments, SIGLEC15 expression is reduced by downregulating the expression of the gene encoding SIGLEC15 through short hairpin RNA (shRNA) transfection. Such protocols are well known in the art (10) and will not be described in detail here. Briefly, a pGPU6 vector carrying SIGLEC15 shRNA can be transfected into lymph node single cells obtained as described above using a transfection kit, such as a kit from Shanghai GenePharma Company (Shanghai, China), according to the manufacturer's instructions. After 48 hours of incubation, knockdown of SIGLEC15 expression is confirmed by RT-PCR. In addition, other protocols and reagents for downregulating the expression of specific genes using shRNA are commercially available from several companies, including ThermoFisher Scientific and Sigma-Aldrich, without any preconceptions.
[0041] In some embodiments, SIGLEC15 expression is reduced by downregulating the expression of the gene encoding SIGLEC15 through CRISPR-mediated gene editing. A CRISPR / Cas9 vector is constructed to target a selected specific site and region within the SIGLEC15 gene. sgRNA is designed using CRISPRdirect (http: / / crispr.dbcls.jp / ). sgRNA oligomers are synthesized and cloned into the pU6gRNACas9EGFP vector. Lymph node single cells are first seeded into 6-well plates and then transfected using Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer's instructions. After incubating the cells for an additional 48 hours, knockout of SIGLEC15 expression was confirmed by RT-PCR and flow cytometry.
[0042] After reducing the expression of SIGLEC15, the extracted cells are cultured ex vivo under conditions that support T cell expansion. Such protocols and reagents are known per se and are available, in particular, under the trade names Gibco™ CTS™ OpTmizer™, CTS AIM V Medium and CTS Immune Cell SR (ThermoFisher Scientific) and from Stem Cell Technologies Inc. (Cambridge, MA, USA) as disclosed in Technical Bulletin No. 27143). Protocols for expanding T cells are also disclosed in WO2018234516 and Chinese Patent Application No. 108220234.
[0043] Generally, a suspension of single cells with reduced SIGLEC15 expression is resuspended in serum-free cell culture medium in the presence of interleukin-2 and / or other cytokines and transferred to a growth vessel such as a flask or plate. The cells are then expanded at 37°C in a 5% CO2-enriched atmosphere and restimulated with tumor antigens along with antigen-presenting cells during cell culture.
[0044] The following protocol (8) is provided as one possible protocol: Single cell suspensions obtained from SLNs were cultured at 4 x 10 cells in X-VIVO™ 15 serum-free cell culture medium (LONZA). 6 The cells are resuspended in the presence of 1000 IU / ml of recombinant human interleukin-2 (Shuanglu, China) at a density of 1000 IU / ml. These cells are seeded into flasks or plates and maintained at 37°C in a humidified atmosphere containing 5% CO2. Autologous tumor lysate is added to the initial culture at a dilution of 1 / 100 (v / v) as previously described (1). To induce highly tumor-specific SLN-T cells, restimulation is performed by adding autologous tumor lysate along with irradiated autologous PBMCs to the SLN-T cell culture. One week before transfusion, 5 ml of culture medium is removed for bacterial and fungal contamination testing using a BACTEC 9120 (Becton-Dickinson) and endotoxin levels are measured based on the Limulus reaction. On the day of transfusion, these assays are repeated to detect any bacterial, fungal, or endotoxin contamination. The lymphocyte subsets of SLN-T cells are analyzed. Additionally, 1 x 10 cells are added to the initial culture at a dilution of 1 / 100 (v / v). 6 Individuals were used for flow cytometry analysis of the tumor surface marker epithelial cell adhesion molecule (EpCAM) to exclude the presence of tumor cells.
[0045] In a further aspect, the present invention relates to a population of T cells having reduced expression of SIGLEC15 obtained or obtainable by the method according to the above aspects.
[0046] In a further aspect, the present invention relates to a population of T cells having reduced expression of SIGLEC15 obtained or obtainable by a method according to the invention for use in medicine.
[0047] In one embodiment of this aspect, the present invention relates to a population of T cells having reduced expression of SIGLEC15 obtained or obtainable by the method described in the above aspect for use in the treatment of cancer, such as the treatment of solid tumors.
[0048] In one embodiment, the present invention relates to the use of autologous T cells in a method for treating cancerous tumors. According to this embodiment, a population of T cells obtained or obtainable by the method described in the above aspect can be used in treating cancerous tumors located in proximity to lymph nodes identified as tumor-draining lymph nodes according to the method described above in a subject from which the tumor-draining lymph nodes have been obtained.
[0049] The cancerous tumor can be any type of solid cancer. A solid cancer according to the present invention is an abnormal mass of tissue occurring in an organ. A solid cancer usually does not contain cysts or liquid areas. A solid cancer can be malignant. Various types of solid cancer are named based on the type of cells that form them. Types of solid cancer include sarcoma, carcinoma, and lymphoma. The present invention provides a composition comprising T cells obtained or obtainable by the method of the present invention.
[0050] Examples of solid tumors include adrenal cancer, anal cancer, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, B-cell lymphoma, bile duct cancer, bladder cancer, brain / CNS tumors, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, Ewing's tumor, eye cancer, gallbladder cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor (gist), gestational trophoblastic disease, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, intravascular large B-cell lymphoma, renal cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer (non-small cell and small cell), pulmonary carcinoid, lymphomatoid granulomatosis, and malignant tumors. The T cells of the present invention are particularly effective in treating solid cancers. Therefore, the subject to be treated by the therapeutic method of the present invention may have a solid cancer. The T cells of the invention are particularly effective in the treatment of solid cancers selected from the group consisting of anal cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, liver cancer, lung cancer (non-small cell and small cell), lung carcinoid, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, gastric cancer, testicular cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and even more particularly for the treatment of breast cancer, colon cancer, liver cancer, lung cancer (non-small cell and small cell), lung carcinoid, pancreatic cancer, prostate cancer, ovarian cancer and bladder cancer.
[0051] In one embodiment, the cancer is selected from the group of colorectal cancer, malignant melanoma, cervical cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC).
[0052] In one aspect, the present invention provides a method of treating a cancerous tumor in a subject, comprising: S1. Identifying lymph nodes in the subject that drain lymph from a cancerous tumor; S2. Extracting cells from the identified lymph nodes; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells having reduced expression of SIGLEC15 under conditions that support T cell expansion; S5. Administering expanded T cells with reduced SIGLEC15 expression; The present invention relates to a method comprising:
[0053] Step S1 can be replaced by step S1' as explained above.
[0054] The method of treatment according to the present invention is shown diagrammatically in FIG.
[0055] Steps S1, S2, S3 and S4 may be performed as described above.
[0056] Administration of expanded T cells can be by intravenous administration, as known in the art. (11) Administration can also be intraarterial, intrathecal, or intraperitoneal.
[0057] The following protocol (8) is provided as one useful protocol for T cell administration. Final SLN-T cells are harvested, washed twice in saline, and transferred to a sterile plastic bag containing 200 ml of saline and 1% human serum albumin (CSL Behring GmbH, Germany). Cells are transfused intravenously over a 60-minute interval according to the hospital's transfusion guidelines. After cell transfusion, transfusion-related toxicity is assessed using the Common Terminology Criteria for Adverse Events (CTCAE) 3.0 criteria.
[0058] The present invention also relates to the use of a population of T cells obtained or obtainable according to the methods described above in the manufacture of a pharmaceutical composition. In one embodiment, the pharmaceutical composition is for use in the treatment of cancer, for example, the treatment of solid tumors.
[0059] The present invention also relates to a pharmaceutical composition comprising a population of T cells obtained or obtainable according to the method described above. In one embodiment, the pharmaceutical composition is for use in a medicine as described above, for example in the treatment of cancer, for example in the treatment of solid tumors.
[0060] The pharmaceutical composition may contain pharmaceutically acceptable excipients common in the art. The pharmaceutical composition is preferably formulated into a liquid suitable for injection, e.g., intravenous, intraarterial, intrathecal, or intraperitoneal administration.
[0061] A "pharmaceutical excipient" or "pharmaceutically acceptable excipient" is a carrier, usually liquid, into which an active therapeutic agent is formulated. In one embodiment of the present invention, the active therapeutic agent is a population of T cells obtained or obtainable by the methods described herein. The excipient generally does not provide any pharmacological activity to the formulation, although it may provide chemical and / or biological stability. Exemplary formulations can be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition, Grennaro, A., ed., 1995, incorporated by reference.
[0062] As used herein, "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier may be suitable for intravenous, intraperitoneal, intramuscular, or sublingual administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, its use in the pharmaceutical compositions of the present invention is contemplated. Supplementary active compounds may also be incorporated into the compositions.
[0063] In carrying out the present invention, one skilled in the art may use methods and protocols known in the art, including, but not limited to, the methods and protocols disclosed in the patent documents and scientific literature referred to herein and the references therein, all of which are incorporated herein by reference. [Example]
[0064] experiment Gene expression analysis Sentinel and non-sentinel lymph nodes were identified as previously described (7). Briefly, a lymphotropic dye (Patent Blue, Sigma-Aldrich) was injected subserosally around the primary tumor. Tumor-draining lymph nodes, i.e., sentinel nodes, were stained blue. Lymph nodes that did not stain were considered non-sentinel nodes.
[0065] Two lymph nodes, one non-metastatic sentinel lymph node (SN) and one non-sentinel lymph node (NSN), were obtained from each of 23 patients diagnosed with colorectal cancer and used to obtain gene expression profiles by high-throughput RNA sequencing technology and bioinformatics analysis.
[0066] Gene expression data was obtained by sequencing lymph node tissue using Ilumina's RNA-SEQ technology.
[0067] A total of 16 genes, including nine up-regulated and seven down-regulated genes, were differentially expressed in sentinel lymph nodes compared with non-sentinel lymph nodes. IL1RL1, STON2, TPSAB1, GATA2, DNAJB4, NR2F1, and DIPK2A were found to be down-regulated, whereas PLA2G2D, ZBED6CL, SIGLEC15, KCNC3, ATP2A1, MMP2-AS1, FBXO41, DSC2, and TFEC were found to be up-regulated.
[0068] Confirmation by RT-PCR Total RNA was extracted from pairs of SN and NSN from eight randomly selected patients from over 23 patients using TRIzol Reagent according to the manufacturer's instructions. cDNA synthesis was performed using the PrimeScript™ RT Reagent Kit and gDNA Eraser (Takara, Japan). Primers for SIGLEC15 and the endogenous reference gene β-actin were designed using Primer5 software. RT-qPCR was performed using TB Green® Premix Ex Taq™ II (Takara, Japan) according to the manufacturer's instructions. Melting curve analysis was performed after PCR to confirm primer specificity, and relative levels of SIGLEC15 were calculated using the 2-ΔΔCt method (12). Relative expression of SIGLEC15 in sentinel lymph nodes before and after siRNA knockdown was analyzed in three sentinel lymph nodes. The results are shown in Tables 1 and 2 and Figure 3.
[0069] [Table 1]
[0070] [Table 2]
[0071] RNAscope in situ hybridization To further explore the expression pattern of SIGLEC15 in lymph nodes, we investigated the expression of SIGLEC15 and CD163 in pairs of SN and NSN from four patients using RNAscope in situ hybridization technology (13), which can provide information about the spatial expression of RNA in tissue cells. The results are disclosed in Table 3 and show that mRNA expression is higher in sentinel lymph nodes (p = 0.042, Student's t test).
[0072] [Table 3]
[0073] According to the results of double staining of SIGLEC15 and CD163 in sentinel and non-sentinel lymph node slices, we further confirmed that SIGLEC15 was highly expressed in SN compared with NSN. In addition, SIGLEC15 was expressed not only in M2 macrophages but also in other cell types.
[0074] From these results, we could further confirm that SIGLEC15 was highly expressed in SN compared with NSN, and that SIGLEC15 was expressed not only in M2 macrophages but also in other cells.
[0075] Flow cytometry analysis We detected SIGLEC15 protein expression on the surface of various cell subsets by flow cytometry.
[0076] Single cell suspensions from SN or NSN and tumor tissues were obtained immediately after surgery by applying gentle pressure using a loose-fit glass homogenizer.
[0077] For SIGLEC15 analysis of cells from SN or NSN, fluorescently labeled monoclonal antibodies (mAbs) against CD45, CD86, CD11c, CD163, CD11b, CD15, CD14, CD3, CD4, CD8, CD16, CD56, CD19, and SIGLEC15 (Biolegend) were used. Cells were incubated in the presence of mAbs according to the manufacturer's recommendations for 20 minutes at room temperature (18-25°C) protected from light. After incubation, the cell suspension was washed with phosphate-buffered saline (PBS), and the cell pellet was resuspended in 0.5 ml of PBS for analysis. Samples were further analyzed using a Navios flow cytometer (Beckman Coulter). At least 50,000 total events were collected and analyzed using Flowjo software (Flowjo LCC).
[0078] SIGLEC15 was highly expressed in almost all subgroups of sentinel lymph nodes (Fig. 4A). In sentinel lymph nodes, SIGLEC15 was highly expressed in M2 macrophages (Fig. 4B). The same trend was observed in non-sentinel lymph nodes (data not shown).
[0079] SIGLEC15 functional analysis To evaluate the role of SIGLEC15 in sentinel lymph nodes, we knocked down SIGLEC15 expression in sentinel lymph nodes using siRNA technology. Briefly, single lymph node cells were transfected with siRNA according to the manufacturer's instructions (GE Dharmacon).
[0080] To confirm the knockout effect, we synthesized a total of three siRNA sequences. The siRNAs were designed according to the RNA sequence of the target gene (SIGLEC15) and in accordance with siRNA design principles using siRNA design software (Invivogen, https: / / www.invivogen.com / sirnawizard / guidelines.php).
[0081] The following siRNA sequences were designed (including the complementary strand and a 3'-TT overhang to prevent degradation by 3'-exonucleases):
[0082] [Table 4]
[0083] 1 μmol / L siRNA was transfected into 96-well tissue culture plates containing Accell siRNA delivery vehicle for 72 hours. RT-PCR was used to evaluate SIGLEC15 mRNA expression in siRNA-transfected and non-transfected groups.
[0084] Flow cytometry was used to detect the mean fluorescence intensity (MFI) of SIGLEC15 protein on the surface of all living cells in the lymph nodes to evaluate the effect of siRNA interference on reducing SIGLEC15 protein expression. The results are shown in Table 5.
[0085] [Table 5]
[0086] Flow cytometry data showed that in cells from sentinel lymph nodes, anti-tumor functional cytokines released by T cells, such as IL-2, TNFα, and IFNγ, were upregulated after SIGLEC15 knockdown (Table 6 and Figure 5).
[0087] [Table 6]
[0088] After SIGLEC15 blockade, functional T cell cytokines are increased, which is recognized as an improved anti-tumor effect of T cells.
[0089] IL2 was secreted primarily by Th1 T cells. IL2 is a marker for activated Th cells, cytotoxic T cells, and NK cells, and it is a necessary factor for the proliferation of activated T cells.
[0090] TNFα is produced primarily by activated T lymphocytes and natural killer (NK) cells. It induces hemorrhagic necrosis in certain tumor types and is used in the local treatment of locally advanced soft tissue sarcomas and metastatic melanoma. TNFα also causes an inflammatory response, which induces more immune cells to kill tumors.
[0091] IFNγ plays a key role in activating cellular immunity and subsequently stimulating antitumor immune responses. It acts as a cytotoxic cytokine together with granzyme B and perforin to initiate apoptosis in tumor cells, but also enables the synthesis of immune checkpoint inhibitory molecules and indoleamine-2,3-dioxygenase (IDO), thus stimulating other immunosuppressive mechanisms.
[0092] As a result, the cytokine release profile indicates the anti-tumor effect of expanded T cells with reduced expression of SIGLEC15.
[0093] References 1. Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. Karlsson, M., et al. 2010, Ann Surg Oncol, Vol. 17, pp. 1747-1757. 2. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Dudley, M.E., et al.,. 4, 2003, Journal of Immunotherapy, Vol. 26, pp. 332-342. 3. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Waldman, A.D., et al. 2020, Nature Reviews Immunology, Vol. 20, pp. 651-668. 4. SIGLEC15: an immune system Siglec conserved throughout vertebrate evolution. Angata, T., et al. 8, 2007, Glycobiology, Vol. 17, pp. 838-846. 5. SIGLEC15 as an immune-suppressor and potential target for normalization cancer immunotherapy. Wang, J. et al. 4, 2019, Nature Medicine, Vol. 25, pp. 656-666. 6. Optimizing CAR-T Cell Manufacturing Process during Pivotal Clinical Trials. Tyagarajan, S., et al. March 2020, Molecular Therapy: Methods & Clinical Development, Vol. 16, pp. 136-144. 7. Identification of sentinel nodes in patients with colon cancer. Dahl, K., et al. 4, May 2005, Eur J Surg Oncol, Vol. 31, pp. 381-385. 8. Phase I / II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Zhen, Y-H, et al. s.l. : Springer, 20 May 2015, Cancer Immunol Immunother. 9. RNA Interference to Knock Down Gene Expression. Han, H. 2018, Methods Mol Biol, Vol. 1706, pp. 293-302. 10. Short Hairpin RNA (shRNA): Design, Delivery, and Assessment. Moore, C.B., et al. 2010, Methods Mol Biol. , Vol. 629, pp. 141-158. 11. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Foppen, M.H.G. et al.,. 2015, M O L E C U L A R ON C O L O G Y, Vol. 9, pp. 1918-1935. 12. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔCT Method. Livak, K.J., et al. 4, December 2001, Methods, Vol. 25, pp. 402-408. 13. RNAscope: A novel in situ RNA analysis platform for formalin-fixed, Paraffin-embedded tissues. Wang, F., et al. 1, 2012, The Journal of Molecular Diagnostics, Vol. 14, pp. 22-29.
Claims
1. A method for obtaining a population of T cells having reduced expression of SIGLEC15, comprising: S1. Identifying lymph nodes that drain lymphatic fluid from a cancerous tumor in a subject; S2. Extracting cells from the identified lymph node; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells having reduced expression of SIGLEC15 under conditions that support T cell expansion; The method includes:
2. A method for obtaining a population of T cells having reduced expression of SIGLEC15, comprising: S1. Providing T cell-containing lymph node tissue removed from a subject, said lymph node tissue being obtained from a lymph node identified in said subject as draining lymphatic fluid from a cancerous tumor; S2. Extracting cells from the identified lymph node; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells having reduced expression of SIGLEC15 under conditions that support T cell expansion; The method includes:
3. The method of claim 1 or 2, wherein the expression of SIGLEC15 is reduced by downregulation of expression of the gene encoding SIGLEC15 by siRNA transfection, shRNA transfection or CRISPR-mediated gene editing.
4. The method according to any one of claims 1 to 3, wherein the expression of SIGLEC15 is reduced by downregulation of expression of the gene encoding SIGLEC15 by siRNA transfection using an siRNA molecule having a nucleotide sequence as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:
6.
5. The method of any one of claims 1 to 4, wherein the conditions that support T cell expansion comprise maintaining the cells in the presence of interleukin-2.
6. A population of T cells having reduced expression of SIGLEC15 obtained or obtainable by the method according to any one of claims 1 to 5 for use in medicine.
7. A population of T cells having reduced expression of SIGLEC15 obtained or obtainable by the method according to any one of claims 1 to 5 for use in a method for the treatment of cancer.
8. 8. The population of T cells for use according to claim 7, wherein the cancer is a solid tumor.
9. 9. The population of T cells for use according to claim 7 or 8, wherein the cancer is the cancerous tumor of the subject from which the T cells are derived, or a metastasis thereof.
10. 10. The population of T cells for use according to any one of claims 7 to 9, wherein the cancer is selected from the group of colorectal cancer, malignant melanoma, cervical cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC).
11. A pharmaceutical composition comprising a population of T cells having reduced expression of SIGLEC15 obtained or obtainable by the method according to any one of claims 1 to 5, and optionally a pharma- ceutically acceptable excipient and or carrier.
12. A population of T cells having reduced expression of SIGLEC15 administered to a subject for the treatment of a cancerous tumor, comprising: The population of T cells S1. Identifying lymph nodes in the subject that drain lymphatic fluid from the cancerous tumor; S2. Extracting cells from the identified lymph node; S3. Reducing the expression of SIGLEC15 in the extracted cells; S4. Expanding the extracted cells having reduced expression of SIGLEC15 under conditions that support T cell expansion; The method includes: A population of T cells.
13. 13. The population of T cells of claim 12, wherein the expression of SIGLEC15 is reduced by downregulation of expression of the gene encoding SIGLEC15 by siRNA transfection, e.g., by using an siRNA molecule having a nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6; shRNA transfection; or CRISPR-mediated gene editing.
14. Use of a population of T cells for the treatment of a cancerous tumor, comprising: The use, wherein the population of T cells is a population of T cells having reduced expression of SIGLEC15 obtained or obtainable by the method according to any one of claims 1 to 5.
